{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:33:10Z","timestamp":1770838390334,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0359-x","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T13:39:05Z","timestamp":1521121145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"first","affiliation":[]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[]},{"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[]},{"given":"Sanna-Kaisa","family":"Herukka","sequence":"additional","affiliation":[]},{"given":"Sylvain","family":"Lehmann","sequence":"additional","affiliation":[]},{"given":"Piotr","family":"Lewczuk","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[]},{"given":"Armand","family":"Perret-Liaudet","sequence":"additional","affiliation":[]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[]},{"given":"Martin R.","family":"Turner","sequence":"additional","affiliation":[]},{"given":"Marcel M.","family":"Verbeek","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"359_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/B978-0-12-804279-3.00008-3","volume":"146","author":"I Zerr","year":"2017","unstructured":"Zerr I, Zafar S, Schmitz M, Llorens F. Cerebrospinal fluid in Creutzfeldt-Jakob disease. Handb Clin Neurol. 2017;146:115\u201324.","journal-title":"Handb Clin Neurol"},{"key":"359_CR2","doi-asserted-by":"crossref","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17(2):162\u201373.","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"359_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"359_CR4","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013;136:2419\u201331.","journal-title":"Brain"},{"key":"359_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795\u2013804.","journal-title":"N Engl J Med"},{"key":"359_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119\u201328.","journal-title":"Lancet Neurol"},{"key":"359_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3233\/JAD-150731","volume":"51","author":"O Bousiges","year":"2016","unstructured":"Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, et al. Diagnostic value of cerebrospinal fluid biomarkers (phospho-Tau181, total-Tau, Abeta42, and Abeta40) in prodromal stage of Alzheimer's disease and dementia with Lewy bodies. J Alzheimers Dis. 2016;51:1069\u201383.","journal-title":"J Alzheimers Dis"},{"key":"359_CR8","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74:1492\u2013501.","journal-title":"JAMA Neurol"},{"key":"359_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, et al. Reference measurement procedure for CSF amyloid beta (Abeta)1-42 and the CSF Abeta1-42\/Abeta1-40 ratio\u2014a cross-validation study against amyloid PET. J Neurochem. 2016;139:651\u20138.","journal-title":"J Neurochem"},{"key":"359_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry. 2004;61:95\u2013102.","journal-title":"Arch Gen Psychiatry"},{"key":"359_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol"},{"key":"359_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292\u2013323.","journal-title":"Alzheimers Dement"},{"key":"359_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol. 2017;16:661\u201376.","journal-title":"Lancet Neurol"},{"key":"359_CR14","doi-asserted-by":"crossref","unstructured":"Lewczuk P, Riederer P, O'Bryant S, Verbeek M, Dubois B, Visser PJ, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2017; in press","DOI":"10.1080\/15622975.2017.1375556"},{"key":"359_CR15","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/nm.2221","volume":"16","author":"K Blennow","year":"2010","unstructured":"Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med. 2010;16:1218\u201322.","journal-title":"Nat Med"},{"key":"359_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrneurol.2014.232","volume":"11","author":"A Lleo","year":"2015","unstructured":"Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol. 2015;11:41\u201355.","journal-title":"Nat Rev Neurol"},{"key":"359_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jalz.2016.09.008","volume":"13","author":"AH Simonsen","year":"2017","unstructured":"Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement. 2017;13:274\u201384.","journal-title":"Alzheimers Dement"},{"key":"359_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jalz.2016.09.009","volume":"13","author":"SK Herukka","year":"2017","unstructured":"Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, et al. Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement. 2017;13:285\u201395.","journal-title":"Alzheimers Dement"},{"key":"359_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13195-014-0075-0","volume":"6","author":"E Portelius","year":"2014","unstructured":"Portelius E, Dean RA, Andreasson U, Mattsson N, Westerlund A, Olsson M, et al. beta-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Abeta5-X peptides through alternative amyloid precursor protein cleavage. Alzheimers Res Ther. 2014;6:75.","journal-title":"Alzheimers Res Ther"},{"key":"359_CR20","doi-asserted-by":"publisher","first-page":"16507","DOI":"10.1523\/JNEUROSCI.3647-11.2011","volume":"31","author":"PC May","year":"2011","unstructured":"May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011;31:16507\u201316.","journal-title":"J Neurosci"},{"key":"359_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81:857\u201370.","journal-title":"Ann Neurol"},{"key":"359_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/ana.22247","volume":"69","author":"M Gunnarsson","year":"2011","unstructured":"Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011;69:83\u20139.","journal-title":"Ann Neurol"},{"key":"359_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1352458513490544","volume":"20","author":"M Axelsson","year":"2014","unstructured":"Axelsson M, Malmestrom C, Gunnarsson M, Zetterberg H, Sundstrom P, Lycke J, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014;20:43\u201350.","journal-title":"Mult Scler"},{"key":"359_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gisslen","year":"2016","unstructured":"Gisslen M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135\u201340.","journal-title":"EBioMedicine"},{"key":"359_CR25","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016;54:1655\u201361.","journal-title":"Clin Chem Lab Med"},{"key":"359_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/acn3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3:216\u201325.","journal-title":"Ann Clin Transl Neurol"},{"key":"359_CR27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IO, Dick KM, Brotherhood E, Gordon E, Fellows A, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87:1329\u201336.","journal-title":"Neurology"},{"key":"359_CR28","doi-asserted-by":"publisher","first-page":"38737","DOI":"10.1038\/srep38737","volume":"6","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Blennow K, Halbgebauer S, Shi S, Ruf V, Oeckl P, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016;6:38737.","journal-title":"Sci Rep"},{"key":"359_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer's disease neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557\u201366.","journal-title":"JAMA Neurol"},{"key":"359_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ana.24552","volume":"79","author":"P Weydt","year":"2016","unstructured":"Weydt P, Oeckl P, Huss A, Muller K, Volk AE, Kuhle J, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79:152\u20138.","journal-title":"Ann Neurol"},{"key":"359_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1212\/WNL.0000000000003688","volume":"88","author":"P Steinacker","year":"2017","unstructured":"Steinacker P, Semler E, Anderl-Straub S, Diehl-Schmid J, Schroeter ML, Uttner I, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology. 2017;88:961\u20139.","journal-title":"Neurology"},{"key":"359_CR32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.neuron.2016.07.007","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:494\u20136.","journal-title":"Neuron"},{"key":"359_CR33","first-page":"12","volume":"87","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"359_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrneurol.2015.173","volume":"11","author":"CE Teunissen","year":"2015","unstructured":"Teunissen CE, Malekzadeh A, Leurs C, Bridel C, Killestein J. Body fluid biomarkers for multiple sclerosis--the long road to clinical application. Nat Rev Neurol. 2015;11:585\u201396.","journal-title":"Nat Rev Neurol"},{"key":"359_CR35","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106\u201312.","journal-title":"Lancet"},{"key":"359_CR36","doi-asserted-by":"publisher","first-page":"10655","DOI":"10.1038\/s41598-017-10922-w","volume":"7","author":"A Franceschini","year":"2017","unstructured":"Franceschini A, Baiardi S, Hughson AG, McKenzie N, Moda F, Rossi M, et al. High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. Sci Rep. 2017;7:10655.","journal-title":"Sci Rep"},{"key":"359_CR37","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914\u201322.","journal-title":"Neurology"},{"key":"359_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2217\/bmm.12.46","volume":"6","author":"M del Campo","year":"2012","unstructured":"del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med. 2012;6:419\u201330.","journal-title":"Biomark Med"},{"key":"359_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/17482968.2011.627589","volume":"13","author":"M Otto","year":"2012","unstructured":"Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012;13:1\u201310.","journal-title":"Amyotroph Lateral Scler"},{"key":"359_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fneur.2015.00179","volume":"6","author":"U Andreasson","year":"2015","unstructured":"Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, et al. A practical guide to immunoassay method validation. Front Neurol. 2015;6:179.","journal-title":"Front Neurol"},{"key":"359_CR41","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1373\/clinchem.2011.178368","volume":"58","author":"A Perret-Liaudet","year":"2012","unstructured":"Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, et al. Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. Clin Chem. 2012;58:787\u20139.","journal-title":"Clin Chem"},{"key":"359_CR42","doi-asserted-by":"crossref","unstructured":"Willemse E, van Uffelen K, Brix B, Engelborghs S, Vanderstichele H, Teunissen C. How to handle adsorption of cerebrospinal fluid amyloid-beta (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Abeta42\/Abeta40 ratio. Alzheimers Dement. 13(8):885\u201392.","DOI":"10.1016\/j.jalz.2017.01.010"},{"key":"359_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fneur.2015.00216","volume":"6","author":"BL Reijs","year":"2015","unstructured":"Reijs BL, Teunissen CE, Goncharenko N, Betsou F, Blennow K, Baldeiras I, et al. The Central Biobank and Virtual Biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases. Front Neurol. 2015;6:216.","journal-title":"Front Neurol"},{"key":"359_CR44","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrd.2017.72","volume":"16","author":"AJ van Gool","year":"2017","unstructured":"van Gool AJ, Bietrix F, Caldenhoven E, Zatloukal K, Scherer A, Litton JE, et al. Bridging the translational innovation gap through good biomarker practice. Nat Rev Drug Discov. 2017;16:587\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"359_CR45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/bs.irn.2015.05.015","volume":"122","author":"C Ibanez","year":"2015","unstructured":"Ibanez C, Cifuentes A, Simo C. Recent advances and applications of metabolomics to investigate neurodegenerative diseases. Int Rev Neurobiol. 2015;122:95\u2013132.","journal-title":"Int Rev Neurobiol"},{"key":"359_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tig.2015.01.004","volume":"31","author":"A Verstraeten","year":"2015","unstructured":"Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31:140\u20139.","journal-title":"Trends Genet"},{"key":"359_CR47","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S1474-4422(16)00127-7","volume":"15","author":"E Cuyvers","year":"2016","unstructured":"Cuyvers E, Sleegers K. Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond. Lancet Neurol. 2016;15:857\u201368.","journal-title":"Lancet Neurol"},{"key":"359_CR48","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00401-016-1612-7","volume":"132","author":"HU Klein","year":"2016","unstructured":"Klein HU, Bennett DA, De Jager PL. The epigenome in Alzheimer's disease: current state and approaches for a new path to gene discovery and understanding disease mechanism. Acta Neuropathol. 2016;132:503\u201314.","journal-title":"Acta Neuropathol"},{"key":"359_CR49","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1038\/emm.2014.117","volume":"47","author":"A Ciechanover","year":"2015","unstructured":"Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med. 2015;47:e147.","journal-title":"Exp Mol Med"},{"key":"359_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1586\/14789450.2016.1111141","volume":"13","author":"C Fredolini","year":"2016","unstructured":"Fredolini C, Bystrom S, Pin E, Edfors F, Tamburro D, Iglesias MJ, et al. Immunocapture strategies in translational proteomics. Expert Rev Proteomics. 2016;13:83\u201398.","journal-title":"Expert Rev Proteomics"},{"key":"359_CR51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cyto.2016.12.021","volume":"91","author":"A Malekzadeh","year":"2017","unstructured":"Malekzadeh A, Twaalfhoven H, Wijnstok NJ, Killestein J, Blankenstein MA, Teunissen CE. Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis. Cytokine. 2017;91:145\u201352.","journal-title":"Cytokine"},{"key":"359_CR52","doi-asserted-by":"publisher","first-page":"e0149821","DOI":"10.1371\/journal.pone.0149821","volume":"11","author":"AL Lind","year":"2016","unstructured":"Lind AL, Wu D, Freyhult E, Bodolea C, Ekegren T, Larsson A, et al. A multiplex protein panel applied to cerebrospinal fluid reveals three new biomarker candidates in ALS but none in neuropathic pain patients. PLoS One. 2016;11:e0149821.","journal-title":"PLoS One"},{"key":"359_CR53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","volume":"8","author":"S Engelborghs","year":"2017","unstructured":"Engelborghs S, Niemantsverdriet E, Struyfs H, Blennow K, Brouns R, Comabella M, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017;8:111\u201326.","journal-title":"Alzheimers Dement (Amst)"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0359-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0359-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T03:21:11Z","timestamp":1660620071000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0359-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0359-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"1 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Teunissen has functioned in advisory boards of Fujirebio and Roche, received non-financial support in the form of research consumables from ADxNeurosciences and Euroimmun, performed contract research or received grants from Janssen prevention center, Boehringer, Brainsonline, AxonNeurosciences, EIP farma, Probiodrug and Roche which are all unrelated to the present work.Dr Otto gave invited talks for Teva, Virion, Fujirebio and Lilly and gave scientific advice to Axon, Biogen, Ionis, Roche and Neuroalliance.Dr Engelborghs has received unrestricted research grants from Janssen Pharmaceutica NV and ADx Neurosciences (paid to institution).Dr Herukka has no conflicts to report.Dr Lehmann received consultation honoraria from Fujirebio Europe.Dr Lewczuk received consultation and lectures honoraria from Innogenetics\/Fujirebio Europe, IBL International, AJ Roboscreen, and Roche.Dr Lle\u00f3 MD, PhD has received speaker honoraria from Novartis, Esteva, Nutricia and Lilly and fees for advisory board meetings for Nutricia, Novartis, Schwabe and Lilly.Dr Perret-Liaudet received funding for travel from Innogenetics\/Fujirebio, Roche, Siemens and AJ Robosceen (in the context of lectures).Dr Tumani received funding for research projects, lectures and travel from Bayer, Biogen, Genzyme, Fresenius, Merck, Novartis, Roche, Siemens Health Diagnostic and Teva.Dr Wiltfang received personal fees (advisory boards or consulting) from Axon Neuroscience, Eli Lilly, Janssen-Cilag GmbH, MSD Sharp & Dohme GmbH, F. Hoffmann-La Roche.Henrik Zetterberg MD, PhD is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. He has served on advisory boards of Roche Diagnostics, Eli Lilly and Pharmasum Therapeutics and has received a travel grant from TEVA.L. Parnetti MD, PhD has received honoraria as a member of advisory boards from Innogenetics\/Fujirebio Europe, IBL International and Roche.Dr Blennow has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.Dr Herukka, Dr Turner MD and Dr Verbeek have no conflicts to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"30"}}